Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profilingAndrew H. Beck, Matt van de Rijn, Shirley Zhu et al.|Oncogene|2009Cited by 150
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourBadreddin Edris, Matt van de Rijn, Íñigo Espinosa et al.|The Journal of Pathology|2012Cited by 77
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Matt van de Rijn, Stephen B. Willingham et al.|Proceedings of the National Academy of Sciences|2013Cited by 55